Loading...
a. Subject to sufficient appropriations to meet the requirements of this subdivision, the department shall make available medication approved by the United States food and drug administration for medication abortion at no cost to a patient at health clinics operated by the department where services relating to sexual health are offered and where the department determines making such medication available would be appropriate for the patient population served by such clinic. At such clinics, the department shall make medication for medication abortion available to a patient who seeks to terminate a pregnancy when the use of such medication is indicated and in accordance with the medically reasonable and good faith professional judgment of such patient's medical provider.
b. The department shall provide counseling and timely referrals to other health facilities and family planning providers in accordance with the assessment of the needs of a patient by the department.
c. Nothing in this section shall require the department to provide to a patient any medication that the department or a medical provider providing services in a health clinic described in subdivision a of this section does not find to be indicated in such provider's professional judgment. Nor shall anything in this section prevent the department from offering any other service not described in this section at any location where it provides medical care.
d. Nothing in this section shall create a private right of action, nor be the basis of a claim of medical malpractice against the department or against any medical provider providing services in a health clinic described in subdivision a of this section.
(L.L. 2022/078, 8/12/2022, eff. 8/12/2023)
a. Definitions. For the purposes of this section, the term “rapid testing” means testing for chlamydia, gonorrhea, or HIV that produces results in the same day.
b. Availability. The department shall make rapid testing available at sites in at least 4 boroughs. Three such sites shall be operational by February 15, 2026, and the fourth such site shall be operational by February 15, 2027. In determining the location of rapid testing sites, the department shall consider community and geographic factors including rates of sexually transmitted infections, availability of other testing services, social determinants of health, including, but not limited to, race, ethnicity, sexual orientation, and gender identity, and other factors the department deems relevant. Within 30 days of determining each such location, the commissioner shall notify in writing the mayor and speaker of the council of the considerations that went into such determination.
c. Outreach. Upon the establishment of any rapid testing site required pursuant to subdivision b of this section, the department shall consult or partner with relevant community-based organizations and shall conduct an education campaign in English and the designated citywide languages as defined in section 23-1101 to inform communities of the locations and availability of rapid testing services. In determining relevant community-based organizations to consult or partner with, the department shall consider community and geographic factors including rates of sexually transmitted infections, availability of other testing services, social determinants of health, including, but not limited to, race, ethnicity, sexual orientation, and gender identity, and other factors the department deems relevant.
d. Disclaimer. Nothing in this section shall require the department to provide rapid testing services to a patient for whom the department or the medical provider administering such services does not find such rapid testing to be clinically appropriate.
(L.L. 2024/084, 8/17/2024, eff. 8/17/2024)
Editor's note: For related unconsolidated provisions, see Appendix A at L.L. 2024/084.
The department shall promulgate rules requiring the department to respond to complaints regarding unsafe lead-based paint work practices.
Editor's note: For related unconsolidated provisions, see Appendix A at L.L. 2004/001.
Loading...